Interview: Chen Qiyu – Chairman, Fosun Pharma, China
Chen Qiyu, chairman of Fosun Pharma, discusses how the company is helping China achieve its ‘Healthy China…
Fosun Pharma
Last updated: 26.11.2018
Address: Fosun Commercial Building No. 2 Fuxing Road (East) Shanghai,
Zip Code：200010
,China
Tel: -23137935
Web: http://www.fosunpharma.com/
Company description
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196), was established in 1994 and listed on Shanghai Stock Exchange in August 1998. Now it has turned a leading listed company in Chinese pharmaceutical industry.
Fosun Pharma’s net profits have increased by 13.55 times since its 13-year listed and its annual compound growth rate has reached 24.26%. Meanwhile, its net assets and net profits are in front rank of the listed companies in Chinese pharmaceutical industry.
Fosun Pharma specializing in modern biological medical & health industry, has taken great opportunities of the rapid growth of China’s medical market and Chinese enterprises’ access to the world’s predominant medical market, and accelerated industry integration and implemented key product strategy by following the business principle of “Brand, Innovation, High-efficiency and Globalization” so as to realize stable operation and rapid development, at the same time, it has become a large pharmaceutical group on the aspect of R&D, innovation, marketing, merging & integration and team building by regarding R&D, manufacturing and distribution of the medicines as the core and taking the lead of the scale and market role in diagnostic medicines and medical instruments.
Products and services
Vertically integrated pharmaceutical company
Interviews
Related
China / Boehringer Ingelheim's Stroke Rehab Centre Success & Continuing China Push
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai…
Haijun Dong – CEO, BioDuro-Sundia
Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of…
China / Public Insurance Coverage for Rare Disease Patients: Beijing & Shanghai Surprisingly Low in New City Ranking
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the…
China / AstraZeneca/Junshi anti-PD-1 Tie-Up; New UK Biologics Plan for Pharmaron; Clover’s $230 Million Investment Boost
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and…
China / Yangtze River Pharmaceutical Group (YRPG) in Profile
One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River…
China / HiFiBiO CEO on the Keys to Global Biotech Success
HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T:…
China / New Drug Approvals 2020
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi…
Liang Schweizer – CEO & CSO, HiFiBiO Therapeutics
Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the…
China / National Reimbursement Drug List (NRDL) 2020: What Reward for Innovation?
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact…
China / New Year, New Round of Drug Price Cuts
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug…
China / 5 Top Trends in Healthcare & Biopharma in 2020
2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being…
Global / 2020's Top 7 Biotech IPOs In Profile
Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of…
